Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality- Global Phase 1 study of CLN-978 in systemic lupus ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has received an average rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports.

Cullinan Therapeutics is a multifocal biotech with promising programs in precision medicine and immunotherapy, despite recent market sentiment declines. Zipalertinib shows potential in treating ...

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has been given an average recommendation of “Buy” by the seven brokerages that are covering the stock, MarketBeat Ratings reports.

MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling over 100 points ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.